Jesse Landry on SeraGene Therapeutics: Rewriting the Rules of Blood and Bleeding Disorders
Jesse Landry, Founder at Jesse Landry, shared on LinkedIn:
”Most people only think about blood when it is spilled or when a lab tech circles a number in red.
SeraGene Therapeutics thinks about it like a system you can tune before anything breaks, turning coagulation into something programmable instead of something you hope stays balanced.
Serum plus genes equals a company reframing how we approach bleeding disorders without theatrics.
Launched in 2022 as a spin-out of the NanoMedicines Innovation Network with scientific roots at Versiti Blood Research Institute and the Center for Blood Research at The University of British Columbia, SeraGene Therapeutics began with real infrastructure and real models, not a slide deck pretending to be a pipeline.
The founding crew, Dr. Christian Kastrup, Dr. Lih Jiin (LJ) Juang, Dr. Amy Wong Strilchuk and Dr. Katie Badior, brings deep hematology, RNA therapeutics and blood biochemistry expertise.
When Dr. Erika Siren stepped in as CEO in 2024 after work across Takeda, e UBC , Toronto, Vancouver and Harvard Medical School, the rare disease and women’s health focus shifted from ambition to strategy.
Pathway to Cures, the venture philanthropy arm of the National Bleeding Disorders Foundation, saw enough traction to lead early funding, with Hextwo Capital beside them.
Around that anchor sits a heavyweight circle: Adage Capital Management, Blue Owl Capital Healthcare Opportunities, Boxer Capital Management, Commodore Capital LP, deeptrack™ Capital, Foresite Capital and Logos Capital.
Those firms do not move unless the science holds up.
Their bet: clot-modifying siRNAs in LNPs, delivered to the liver to tune the fibrinolytic pathway.
Adjust plasminogen here, shift expression there, and you get long-acting prophylaxis lasting weeks from one dose—>10x longer than standard care.
Lead program SG-001 showed strong non-human primate data at ASH 2024.
Eight patents span antifibrinolytic RNA-LNPs, mRNA therapies for rare bleeding disorders, ADAMTS13 and fibrinogen knockdown and PAI-1 modulation.
A real pipeline, not a single swing.
Through their lens, the opportunity widens fast: VWD, hemophilia, rare factor deficiencies, platelet dysfunction, thrombosis and cardiovascular disease, all addressable through durable, liver-targeted RNA control.
Add the disproportionate impact on women and girls, and Siren’s focus becomes mission-level.
Recognition followed: “Company to Watch” from Life Sciences BC, Coup de Coeur at Sweet Pharma Day, placement in the Life Sciences BC Investor Readiness Program, finalist at the Eli Lilly and Company Grand Challenge and an Amgen Golden Ticket from UBC.
If you work in hematology, rare disease, womens health or cardiovascular care, SeraGene Therapeutics is a name you will keep seeing.
The science is tight, the team sharp and the window still early.”
Stay updated with Hemostasis Today.
-
Nov 24, 2025, 10:25Jean Jacques Kiladjian Visits INSERM-supervised CIC 1408 Investigation Center
-
Nov 24, 2025, 10:06Amirpasha Moetazedian Invites a PHD Student to His Lab to Explore Sustainable Artificial Blood Vessels
-
Nov 24, 2025, 09:41Kamran Hajiyev Reflects on A Week of Innovation, Collaboration, and Scientific Exchange at SVIN 2025
-
Nov 24, 2025, 02:55Do You Know Why Clot Contracts? Marin Pavlov Reflects on Expert PE Conference 2025
-
Nov 24, 2025, 01:39Ashkan Shoamanesh Shares OCEANIC-STROKE Trial’s Successful Endpoints
-
Nov 24, 2025, 01:10Swarsat K Nath on HemeNext 2025: AI is Real, Measurable, and Already Changing Lives
-
Nov 23, 2025, 15:15Dirk Sibbing on OCEANIC-STROKE Demonstrationg Superiority of Asundexian vs. Placebo
-
Nov 23, 2025, 14:49Reza Shojaei: What Truly Motivates Donors And What Keeps Them Coming Back?
-
Nov 23, 2025, 14:48Michael Davidson: Why LDL Alone Isn’t Enough for CV Risk Reduction